These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29952180)

  • 1. Apalutamide and Metastasis-free Survival in Prostate Cancer.
    Rachner TD; Tsourdi E; Hofbauer LC
    N Engl J Med; 2018 Jun; 378(26):2541-2. PubMed ID: 29952180
    [No Abstract]   [Full Text] [Related]  

  • 2. Apalutamide and Metastasis-free Survival in Prostate Cancer.
    Smith MR; Yu MK; Small EJ
    N Engl J Med; 2018 Jun; 378(26):2542. PubMed ID: 29949495
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Heinrich D; Russnes KM; Oldenburg J
    Eur Urol; 2018 Aug; 74(2):236-237. PubMed ID: 29691083
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Haidl F; Heidenreich A; Pfister D
    Eur Urol; 2018 Aug; 74(2):237-238. PubMed ID: 29653884
    [No Abstract]   [Full Text] [Related]  

  • 5. Filling a True Unmet Need: A New Therapy for Nonmetastatic Castrate-resistant Prostate Cancer Commentary on: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Kesch C; Black PC
    Urology; 2018 Jun; 116():1-2. PubMed ID: 29596865
    [No Abstract]   [Full Text] [Related]  

  • 6. Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer.
    Klotz L
    N Engl J Med; 2019 Jul; 381(1):84-86. PubMed ID: 31269371
    [No Abstract]   [Full Text] [Related]  

  • 7. Apalutamide (Erleada) for prostate cancer.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
    [No Abstract]   [Full Text] [Related]  

  • 8. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
    Rathkopf DE; Antonarakis ES; Shore ND; Tutrone RF; Alumkal JJ; Ryan CJ; Saleh M; Hauke RJ; Bandekar R; Maneval EC; de Boer CJ; Yu MK; Scher HI
    Clin Cancer Res; 2017 Jul; 23(14):3544-3551. PubMed ID: 28213364
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Taneja SS
    J Urol; 2019 Oct; 202(4):661. PubMed ID: 31294666
    [No Abstract]   [Full Text] [Related]  

  • 11. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO].
    Rexer H; Graefen M
    Urologe A; 2017 Feb; 56(2):243-244. PubMed ID: 28144693
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Sakamoto S
    Int J Urol; 2021 Mar; 28(3):288. PubMed ID: 33327040
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
    Beaver JA; Kluetz PG; Pazdur R
    N Engl J Med; 2018 Jun; 378(26):2458-2460. PubMed ID: 29949489
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    Spahn M
    Eur Urol; 2018 Jan; 73(1):141-142. PubMed ID: 29033103
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
    Sasaki D; Hatakeyama S; Tanaka T; Okamoto T; Yoneyama T; Ohyama C
    Int J Urol; 2022 Jul; 29(7):772-773. PubMed ID: 35285092
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men with Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2016 Sep; 196(3):742. PubMed ID: 27597066
    [No Abstract]   [Full Text] [Related]  

  • 17. Primary cryoablation nadir prostate specific antigen and biochemical failure.
    Levy DA; Pisters LL; Jones JS
    J Urol; 2009 Sep; 182(3):931-7. PubMed ID: 19616226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis.
    Ciezki JP; Reddy CA; Kupelian PA; Klein EA
    Urology; 2012 Aug; 80(2):367-72. PubMed ID: 22857756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles.
    Pang X; Wang Y; Chen Y
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2803-2806. PubMed ID: 28478926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis.
    Umezawa R; Inaba K; Nakamura S; Wakita A; Okamoto H; Shima S; Tsuchida K; Kashihara T; Kobayashi K; Harada K; Takahashi K; Murakami N; Ito Y; Igaki H; Jingu K; Itami J
    Anticancer Res; 2018 Apr; 38(4):2303-2309. PubMed ID: 29599353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.